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A B S T R A C T
Primary ovarian carcinosarcoma is a rare biphasic tumor. There is variable admixture of both malignant epithelial and stromal 
component seen in this tumor. We report a case of a primary carcinosarcoma of ovary in a 72‑year‑old post‑menopausal female 
presenting with the complaint of abdominal distension. Staging laparotomy was done for this patient, and final histopathology 
was reported as the carcinosarcoma of ovary. The epithelial and sarcomatous components showed immunohistochemical 
positivity for their respective markers.
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INTRODUCTION
Primary ovarian carcinosarcoma is a rare tumor. It accounts 
for 1-3% of ovarian malignancies. By definition, in this tumor, 
both epithelial and stromal components are malignant. 
It is also known as malignant mixed mesodermal tumor 
or malignant mixed Mullerian tumor. They are further 
sub-classified as “heterologous” or “homologous.” This 
categorization is based on the presence or absence of a 
stromal component containing mesenchymal tissue not 
normally found at the primary tumor site.[1] Usually, there 
is the extra-ovarian intra-abdominal spread at the time of 
diagnosis in the majority of the cases. The primary treatment 
has traditionally been surgical cytoreduction, followed by 
radiotherapy and chemotherapy or chemotherapy alone.[2] 
These tumors are aggressive in nature with poor prognosis.[1]
Hereby, we present a case of a primary carcinosarcoma of ovary 
in a 72-year-old female highlighting the histopathological 
and immunohistochemical findings.
CASE REPORT
A 72-year-old post-menopausal female presented with 
distension of abdomen of 2 months duration. She also had a 
complaint of pain in the lower abdomen since 1 month. She 
had no history of bleeding or white discharge per vaginum. 
There was a history of loss of weight and appetite. She did 
not give any previous history of surgery. She was a known 
hypertensive patient on irregular treatment. She was not a 
known diabetic.
Her abdomen was distended. She had a vague lump of size 
about 15 × 12 cm present in the lower abdomen. The lump 
was extending up to the epigastrium and was mobile. The 
lower part of the lump could not be palpated.
Cervix was atrophic as revealed by per vaginal examination. 
Per rectal examination did not reveal any abnormality.
The ultrasound examination of the abdomen showed left 
abdomino-pelvic mass. The contrast-enhanced computed 
tomography (CT) of the abdomen showed a large, 
hypodense, rim enhancing, multilobulated lower abdominal 
mass of 15 × 19 × 17 cm with enhancing mural component, 
arising from the left ovary. The right ovary appeared to be 
normal [Figures 1 and 2]. The uterus was atrophic. There 
was no significant abdominal lymphadenopathy. The ascites 
was moderate. The cytological examination of the ascitic 
fluid did not reveal any malignant cell.
The level of cancer antigen (CA)-125 was elevated 
(160.30 IU/ml, normal <35 IU/ml). The routine hematological 
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and biochemical investigations were within the normal 
limit.
A staging laparotomy was planned. The intra-operative 
findings showed a complex ovarian cyst measuring 
20 × 15 × 12 cm arising from the left ovary and adherent 
to mesentery and part of the small bowel. The tumor tissue 
was protruding out of the capsule and was adherent to the 
small bowel loops. There were no significant para-aortic or 
pelvic lymph nodes. The omentum was thickened without 
any distinct nodular deposits. Peritoneal deposits were 
also not noted. There was the presence of about 2000 ml 
of free fluid. Bilateral pelvic lymph node dissection 
and para-aortic lymph nodal sampling were done. 
Peritoneal biopsies were taken from five quadrants. Total 
omentectomy was done.
Cut section of a large irregular mass showed both solid 
and cystic areas [Figure 3]. Microscopically there were 
micropapillae with pleomorphic cells and hyperchromatic 
nuclei. The stroma showed presence of oval to 
spindle-shaped cells with pleomorphic hyperchromatic 
nuclei and moderate amount of eosinophilic cytoplasm 
giving the rhabdoid appearance. Mitotic activity was 
frequent (8-9/10 high power field). There was also 
the presence of tumor necrosis and lymphatic emboli 
[Figures 4 and 5].
Immunohistochemistry showed cytokeratin and epithelial 
membrane antigen positivity in the epithelial component 
and the rhabdoid looking cells were positive for desmin 
[Figures 6 and 7]. Lymph nodes were reactive in nature. 
Based on the histopathological and immunohistochemical 
findings, the final diagnosis was given as the carcinosarcoma 
of ovary.
The patient had an uneventful post-operative period. She 
was advised medical oncology consultation following 
surgery. However, even after 6 months of surgery, she failed 
to turn up for further management.
Figure 1: Contrast enhanced CT axial images showing large hypodense 
lesion with enhancing solid component peripherally and few septations 
within in the lower abdomen
Figure 2: Contrast enhanced CT sagittal reconstruction images showing 
large hypodense lesion suggestive of malignant ovarian tumor
Figure 3: Cut section of resected ovarian mass with areas of necrosis
Figure 4: Microscopically the ovarian tumor showing presence of both 
epithelial (arrow) and stromal component (Hematoxylin and eosin, ×40)
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malignant mixed tumor, malignant mixed mesodermal 
tumors or malignant mixed Mullerian tumor. However, 
unlike its uterine counterpart, the incidence of ovarian 
carcinosarcoma is quite low. Therefore, the literature 
regarding primary ovarian carcinosarcoma is sparse. These 
biphasic tumors are defined by the histological presence 
of intermixed malignant epithelial and stromal elements. 
Recent studies suggest a monoclonal theory of histogenesis 
for ovarian carcinosarcomas. These studies have proposed 
that because of metaplastic transformation of the epithelial 
component, tumorigenesis results in giving rise to the 
sarcomatous component.[1]
These tumors tend to occur in older women and follow an 
aggressive clinical course when compared to that in the 
epithelial ovarian tumors.[3]
Our patient was a post-menopausal female of 72 years of 
age.
Pre-operative suspicion or confirmation of the diagnosis 
of primary ovarian carcinosarcoma remains quite 
challenging. The clinical and radiological findings 
are practically indistinguishable from other ovarian 
surface epithelial tumors. Tumor markers like CA-125 
may not be elevated in all the cases. Even cytological 
analysis of ascitic fluid may not always reveal malignant 
component.
In our patient, there was the presence of a large abdominal 
lump and associated pain. The CT findings suggested an 
ovarian tumor. The definitive diagnosis of carcinosarcoma 
was made by histopathological examination of the resected 
specimen. The biphasic component was further highlighted 
by the immunohistochemical analysis.
In a study by Menon et al., preoperative raise of CA-125 was 
noted in 9 out of the 12 cases of ovarian carcinosarcoma. 
The hemorrhagic ascitic fluid revealed adenocarcinomatous 
component in four of their cases.[1]
In our case, CA-125 was elevated. However, the ascitic fluid 
cytology did not show any malignancy.
In ovarian carcinosarcoma, there is the presence of both 
intermixed malignant epithelial and stromal component. 
Boucher et al., in their series of ovarian carcinosarcomas, 
have described equal representation of the epithelial 
endometrioid and serous component types. The 
mesenchymal component was largely heterologous, of 
chondromatous and rhabdomyoblastic differentiation.[4] In 
another study, Kunkel et al. had an overwhelming serous 
carcinoma component with a predominance of heterologous 
chondromatous component.[5] In a recent study by 
Figure 5: Rhabdoid looking cells with vesicular nuclei eosinophilic 
cytoplasm (Hematoxylin and eosin, ×20)
Figure 6: Cytokeratin positivity for the epithelial component 
(Immunohistochemistry, ×20)
Figure 7: Desmin positivity in the rhabdoid cells (Immunohistochemistry, 
×20)
DISCUSSION
The synonyms of carcinosarcoma of ovary include 
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Menon et al. they found endometrioid carcinoma and 
heterologous rhabdomyosarcoma as predominant epithelial 
and mesenchymal component respectively.[1]
In our case, we have noted the presence of the epithelial 
component as serous carcinoma and stromal component 
as rhabdomyosarcoma. These two components were 
demonstrated both histopathologically as well as by means 
of immunohistochemistry.
Primary ovarian carcinosarcomas are very aggressive and 
are usually diagnosed at an advanced age and an advanced 
stage of disease.[6]
The adverse prognostic factors as enumerated by various 
studies include advanced age, advanced stage, suboptimal 
cytoreduction, stromal predominant tumors and tumors with 
serous epithelial component.[1,7] Few studies consider the 
initial stage of the disease at the time of diagnosis as the only 
prognostic factor.[8] In our case, though there was a rupture 
of the tumor, there were no omental or peritoneal deposits.
There is no existing consensus regarding treatment of ovarian 
carcinosarcoma. However, surgical treatment is regarded 
as the best option for the survival of patients.[8] The most 
effective treatment consists of optimal debulking, followed 
by paclitaxel and/or platinum-based chemotherapy.[9,10]
Various chemotherapeutic regimes have included cisplatin 
alone; a combination of doxorubicin, ifosfamide, dacarbazine, 
cyclophosphamide, taxol; and other combinations.[2] 
Response rates to chemotherapy are about 20%.[8]
The survival for both early and late stage carcinosarcoma 
is inferior to serous tumors of the ovary.[3] The average 
survival for a woman diagnosed with carcinosarcoma of the 
ovary is <2 years.[11]
New modalities of treatment are being explored to treat this 
uncommon tumor. Trop-2 is overexpressed in a proportion 
of uterine and ovarian carcinosarcomas, and hRS7, a 
humanized anti-Trop-2 antibody, may represent a novel, 
potentially highly effective treatment option for patients 
with treatment-refractory carcinosarcomas overexpressing 
Trop-2.[12] Human epidermal growth factor-2/neu may also 
represent another novel target for the immunotherapy of 
a subset of human carcinosarcomas refractory to salvage 
chemotherapy.[13]
This case is being presented for its relative uncommon 
nature, emphasizing the histopathological features.
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